Literature DB >> 8994759

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia.

J W Chow1, S M Donahedian, M J Zervos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 8994759     DOI： 10.1093/clinids/24.1.90

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  16 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.

Authors:  Issam I Raad; Hend A Hanna; Ray Y Hachem; Tanya Dvorak; Rebecca B Arbuckle; Gassan Chaiban; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic.

Authors:  C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-01

5.  Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

7.  Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

Authors:  M A Schouten; A Voss; J A Hoogkamp-Korstanje
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 8.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

10.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.